XKRX099430
Market cap289mUSD
Dec 27, Last price
7,350.00KRW
1D
0.55%
1Q
40.54%
IPO
-7.40%
Name
BioPlus Co Ltd
Chart & Performance
P/E
16.65
P/S
6.55
EPS
441.57
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
65.04b
+14.68%
Net income
25.58b
+21.02%
CFO
16.04b
+20.07%
Dividend
Dec 27, 202370 KRW/sh
Profile
Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms. In addition, it offers mesotherapy products, such as skin rejuvenation products under the Kiara Reju name; Slim Slimmer, a lipolysis solution; LumiDew, a whitening solution; JuveniHill, an anti-wrinkle solution; and hair scalp care, hair treatment, hair nutrition solutions under the BelloHa and BellaChe names, as well as cosmetics comprising heparinoid essence, EGF ball, and skin care gel under the La Bella name. The company was founded in 2003 and is based in Seongnam-si, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 65,042,901 14.68% | 56,718,819 51.58% | 37,418,198 53.56% | ||
Cost of revenue | 29,866,723 | 26,708,630 | 16,081,125 | ||
Unusual Expense (Income) | |||||
NOPBT | 35,176,178 | 30,010,188 | 21,337,073 | ||
NOPBT Margin | 54.08% | 52.91% | 57.02% | ||
Operating Taxes | 5,318,384 | 6,763,020 | 3,494,686 | ||
Tax Rate | 15.12% | 22.54% | 16.38% | ||
NOPAT | 29,857,794 | 23,247,169 | 17,842,387 | ||
Net income | 25,580,547 21.02% | 21,136,873 97.09% | 10,724,704 10.53% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (4,690,070) | 11,292,053 | 36,706,791 | ||
BB yield | 1.16% | -2.80% | -10.16% | ||
| Debt | |||||
Debt current | 493,508 | 564,275 | 1,812,379 | ||
Long-term debt | 2,619,044 | 1,128,805 | 1,095,821 | ||
Deferred revenue | |||||
Other long-term liabilities | 21,793,339 | 21,798,067 | 68,500 | ||
Net debt | (50,850,857) | (23,218,073) | (46,885,774) | ||
| Cash flow | |||||
Cash from operating activities | 16,040,496 | 13,359,309 | 13,352,360 | ||
CAPEX | (21,092,466) | (6,694,144) | (15,357,670) | ||
Cash from investing activities | 21,728,409 | (67,130,231) | (22,634,220) | ||
Cash from financing activities | (14,460,732) | 30,659,220 | 34,044,570 | ||
FCF | (6,375,723) | 6,893,074 | (186,147) | ||
| Balance | |||||
Cash | 65,001,777 | 78,951,329 | 41,028,457 | ||
Long term investments | (11,038,367) | (54,040,176) | 8,765,517 | ||
Excess cash | 50,711,264 | 22,075,212 | 47,923,064 | ||
Stockholders' equity | 108,279,039 | 78,756,718 | 35,834,452 | ||
Invested Capital | 101,380,047 | 107,743,443 | 43,263,919 | ||
ROIC | 28.56% | 30.79% | 61.57% | ||
ROCE | 21.67% | 22.82% | 26.37% | ||
| EV | |||||
Common stock shares outstanding | 59,077 | 58,116 | 52,561 | ||
Price | 6,870.00 -1.01% | 6,940.00 0.95% | 6,875.00 | ||
Market cap | 405,862,260 0.63% | 403,326,650 11.61% | 361,357,150 | ||
EV | 365,256,104 | 381,803,736 | 316,296,876 | ||
EBITDA | 37,666,428 | 31,897,016 | 22,634,662 | ||
EV/EBITDA | 9.70 | 11.97 | 13.97 | ||
Interest | 60,279 | 13,304 | 521,472 | ||
Interest/NOPBT | 0.17% | 0.04% | 2.44% | ||